We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+41.71%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$596M
AUM Growth
+$276M
Cap. Flow
+$184M
Cap. Flow %
30.8%
Top 10 Hldgs %
91.55%
Holding
21
New
2
Increased
–
Reduced
1
Closed
1
Avg Time Held
7.1 quarters
Top 10 Avg Time Held
6.8 quarters
Top 20 Avg Time Held
7.1 quarters

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$183M
2
ADVM icon
Adverum Biotechnologies
ADVM
+$2.37M

Top Sells

Rank Stock Value
1
KZR icon
Kezar Life Sciences
KZR
+$1.16M
2
SYBX icon
Synlogic
SYBX
+$647K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PHAT icon
1
Phathom Pharmaceuticals
PHAT
$566M
$227M 38.04%
+7,284,269
New +$183M
2019 Q4
0 quarters
MIRM icon
2
Mirum Pharmaceuticals
MIRM
$5.17B
$87.5M 14.67%
3,566,912
– –
2019 Q3
1 quarter
KRYS icon
3
Krystal Biotech
KRYS
$9.51B
$49.6M 8.31%
895,000
– –
2018 Q3
5 quarters
IOVA icon
4
Iovance Biotherapeutics
IOVA
$6.57B
$48.5M 8.13%
1,750,665
– –
2016 Q2
14 quarters
COLL icon
5
Collegium Pharmaceutical
COLL
$701M
$38.8M 6.51%
1,887,332
– –
2015 Q4
16 quarters
ANAB icon
6
AnaptysBio
ANAB
$1.36B
$37.6M 6.31%
2,316,447
– –
2017 Q1
11 quarters
GRTS icon
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$18.5M 3.1%
2,061,758
– –
2018 Q3
5 quarters
TBIO icon
8
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$17.8M 2.98%
2,182,789
– –
2019 Q2
2 quarters
APTX
9
DELISTED
Aptinyx Inc. Common Stock
APTX
$10.9M 1.83%
3,190,079
– –
2018 Q2
6 quarters
ALPN icon
10
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.87M 1.66%
2,571,450
– –
2017 Q3
9 quarters
TPST icon
11
Tempest Therapeutics
TPST
$11.5M
$9.41M 1.58%
7,162
– –
2018 Q4
4 quarters
ALNA
12
DELISTED
Allena Pharmaceuticals
ALNA
$9.09M 1.52%
3,330,373
– –
2017 Q4
8 quarters
ITRM icon
13
DELISTED
Iterum Therapeutics
ITRM
$6.92M 1.16%
102,554
– –
2018 Q2
6 quarters
ETTX
14
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$6.71M 1.13%
1,349,953
– –
2018 Q3
5 quarters
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$5.62M 0.94%
17,026
– –
2018 Q3
5 quarters
CDTX icon
16
DELISTED
Cidara Therapeutics
CDTX
$5.04M 0.85%
65,613
– –
2015 Q4
16 quarters
ADVM icon
17
DELISTED
Adverum Biotechnologies
ADVM
$3.09M 0.52%
+26,834
New +$2.37M
2019 Q4
0 quarters
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.78M 0.47%
202,803
– –
2015 Q4
16 quarters
BLCM
19
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.36M 0.23%
105,144
– –
2018 Q2
6 quarters
KZR icon
20
DELISTED
Kezar Life Sciences
KZR
$363K 0.06%
9,058
-37,716
-81% -$1.16M
2018 Q2
6 quarters
SYBX icon
21
DELISTED
Synlogic
SYBX
– –
-18,843
Closed -$647K –

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q4 2019 Portfolio in Review

As of Q4 2019, Frazier Management held 21 positions worth $596M, up 86% from $320M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Frazier Management deployed $184M of net new capital in Q4 2019, opening 2 new positions. Its largest new stake was Phathom Pharmaceuticals: 7,284,269 shares worth $227M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Kezar Life Sciences, an estimated $1.16M trimmed.

  • Frazier Management's largest Q4 2019 buy was Phathom Pharmaceuticals: 7,284,269 shares worth $227M.
  • Frazier Management's biggest Q4 2019 reduction was Kezar Life Sciences, cutting an estimated $1.16M.
  • Frazier Management fully exited Synlogic in Q4 2019, selling an estimated $647K.
  • Frazier Management's ten largest holdings make up 92% of its $596M portfolio in Q4 2019.
  • Frazier Management opened 2 new positions and closed 1 in Q4 2019.
  • Frazier Management's portfolio value rose 86% quarter-over-quarter to $596M.

Based on Frazier Management's 13F filing for Q4 2019, filed 13 Feb 2020.